Sustained Postoperative Pain Management  Without Risk of Opioid Addiction with Anthony Mack Virpax Pharma episode artwork

EPISODE · Oct 18, 2023 · 20 MIN

Sustained Postoperative Pain Management Without Risk of Opioid Addiction with Anthony Mack Virpax Pharma

from Empowered Patient Podcast · host Karen Jagoda

Anthony Mack, CEO of Virpax Pharma, is developing non-addictive pain drugs focusing on repurposing existing molecules and improving the delivery platform to enhance bioavailability and sustained delivery. With an initial focus on postoperative pain management and preventing opioid tolerance, their product, Probudur, is a long-lasting local anesthetic for sustained pain control. The asset Envelta uses a molecular envelope technology to protect enkephalin as it passes through the blood-brain barrier to attach to delta receptors in the brain to control pain.   Anthony explains, "Now, in the case of the enkephalin asset, as far as tolerance is concerned, we have a product that isn't enkephalin. It's a peptide, and peptides are endogenous materials already in our bodies. Now, we can't generate enough to have pain control, so it would be nice if we could administer them. If an enkephalin can get past the blood-brain barrier, it attaches to the brain's delta receptors. There are immune receptors in the brain, too, that everybody's familiar with because they know morphine, oxycodone, Oxycontin, hydrocodone, and Vicodin. They know these actives, but the problem is that when they attach to these mu receptors, there is a potential for respiratory depression, drug-seeking behavior, and intolerance."   "Yes, that is a great collaboration we have. It's an open, what we call CRADA, or some people may call it an in-kind grant, but it's a cooperation agreement for all of our pain assets, including Envelta. But we started with the Probudur asset because the US Army wanted to study the long-acting bupivacaine in battlefield wound injuries. What they want to do is be able to inject this asset at a wound site and have the soldiers participate in their evacuation, should they need to evacuate."   "The great thing about liposomal bupivacaine in our Probudur formulation is it does not cause a motor block. What I mean by that is because local anesthetics stay numb, in this case, you're still able to function, you're still able to move your extremities. The idea here is that it would block it for 96 hours, enough time for a soldier to extract themselves without so much assistance or without the use of an opioid to block their pain." #VirpasPharma #PainManagement #NonAddictive #PainControl VirpaxPharma.com Download the transcript here  

Episode metadata supplied by the publisher feed · Published Oct 18, 2023

Embed this episode

NOW PLAYING

Sustained Postoperative Pain Management Without Risk of Opioid Addiction with Anthony Mack Virpax Pharma

0:00 20:19

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Empowered Patient Podcast?

This episode is 20 minutes long.

When was this Empowered Patient Podcast episode published?

This episode was published on October 18, 2023.

Can I download this Empowered Patient Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!